Cenegermin
| Clinical data | |
|---|---|
| Trade names | Oxervate |
| Other names | cenegermin-bkbj, Recombinant human nerve growth factor; rhNGF; human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619001 |
| License data |
|
| Pregnancy category |
|
| Routes of administration |
Ophthalmic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C583H908N166O173S8 |
| Molar mass | 13267.15 g·mol−1 |
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor (rhNGF), is a recombinant form of human nerve growth factor (NGF). In July 2017, it was approved in the European Union as an eye drop formulation for the treatment of moderate or severe neurotrophic keratitis in adults.
As a recombinant form of NGF, cenegermin is a peripherally selective agonist of the TrkA and LNGFR (p75NTR) which must be administered parenterally.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
History
It was developed by Anabasis Pharma, Dompé Farmaceutici, and Ospedale San Raffaele.
Research
In addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma.
Further reading
- Sheha H, Tighe S, Hashem O, Hayashida Y (October 2019). "Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis". Clin Ophthalmol. 13: 1973–1980. doi:10.2147/OPTH.S185184. PMC 6789413. PMID 31631965.
External links
- "Cenegermin". Drug Information Portal. U.S. National Library of Medicine.